OBJECTIVES: A single-item indicator of disease activity over an extended period of time, the Manitoba Inflammatory Bowel Disease Index (MIBDI), is introduced and compared against several standard measures for assessing activity in patients with Crohn's disease (CD) and ulcerative colitis (UC). METHODS: Participants enrolled in the Manitoba IBD Cohort Study, a population-based longitudinal cohort study (N=353), were assessed semiannually by survey, clinical interview, and blood sample during a 2-year period. The MIBDI is based on patient self-reports of symptom persistence for the previous 6 months, using a 6-level response format. RESULTS: The MIBDI had good sensitivity compared with the Harvey-Bradshaw Index (HB; 0.88), Powell-Tuck Index (PT; 0.84), and Inflammatory Bowel Disease Questionnaire (IBDQ; 0.89), which was maintained at two subsequent annual measurements. Test-retest reliability was also strong (Spearman's r=0.81). Discriminant function analyses identified common discriminating variables of active disease for CD and UC that included HB, PT, and IBDQ subscales of bowel and systemic symptoms, prolonged symptom severity (e.g., abdominal and joint pain, tiredness, diarrhea), and recent persistent pain related to IBD. Unique discriminators included weight problems (CD) and blood in stool (UC). CONCLUSIONS: A single-item, patient-defined disease activity measure, the MIBDI, showed a high degree of sensitivity for classifying individuals with regard to disease status over time compared with the existing disease activity measures, and strong convergent validity with expected proxy measures of disease. These relationships remained consistent over time. Thus, the MIBDI shows promise as a valid, brief tool for measuring disease activity over an extended period.
OBJECTIVES: A single-item indicator of disease activity over an extended period of time, the Manitoba Inflammatory Bowel Disease Index (MIBDI), is introduced and compared against several standard measures for assessing activity in patients with Crohn's disease (CD) and ulcerative colitis (UC). METHODS:Participants enrolled in the Manitoba IBD Cohort Study, a population-based longitudinal cohort study (N=353), were assessed semiannually by survey, clinical interview, and blood sample during a 2-year period. The MIBDI is based on patient self-reports of symptom persistence for the previous 6 months, using a 6-level response format. RESULTS: The MIBDI had good sensitivity compared with the Harvey-Bradshaw Index (HB; 0.88), Powell-Tuck Index (PT; 0.84), and Inflammatory Bowel Disease Questionnaire (IBDQ; 0.89), which was maintained at two subsequent annual measurements. Test-retest reliability was also strong (Spearman's r=0.81). Discriminant function analyses identified common discriminating variables of active disease for CD and UC that included HB, PT, and IBDQ subscales of bowel and systemic symptoms, prolonged symptom severity (e.g., abdominal and joint pain, tiredness, diarrhea), and recent persistent pain related to IBD. Unique discriminators included weight problems (CD) and blood in stool (UC). CONCLUSIONS: A single-item, patient-defined disease activity measure, the MIBDI, showed a high degree of sensitivity for classifying individuals with regard to disease status over time compared with the existing disease activity measures, and strong convergent validity with expected proxy measures of disease. These relationships remained consistent over time. Thus, the MIBDI shows promise as a valid, brief tool for measuring disease activity over an extended period.
Authors: G Pellino; D S Keller; G M Sampietro; V Annese; M Carvello; V Celentano; C Coco; F Colombo; N Cracco; F Di Candido; M Franceschi; S Laureti; G Mattioli; L Pio; G Sciaudone; G Sica; V Villanacci; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi Journal: Tech Coloproctol Date: 2020-01-25 Impact factor: 3.781
Authors: Tolulope T Sajobi; Lisa M Lix; Ian Clara; John Walker; Lesley A Graff; Patricia Rawsthorne; Norine Miller; Linda Rogala; Rachel Carr; Charles N Bernstein Journal: Qual Life Res Date: 2011-04-24 Impact factor: 4.147
Authors: Marina Arvanitis; Darren A DeWalt; Christopher F Martin; Millie D Long; Wenli Chen; Beth Jaeger; Robert S Sandler; Michael D Kappelman Journal: J Pediatr Date: 2016-05-02 Impact factor: 4.406
Authors: Lisa M Lix; Tolulope T Sajobi; Richard Sawatzky; Juxin Liu; Nancy E Mayo; Yuhui Huang; Lesley A Graff; John R Walker; Jason Ediger; Ian Clara; Kathryn Sexton; Rachel Carr; Charles N Bernstein Journal: Qual Life Res Date: 2012-06-15 Impact factor: 4.147
Authors: Georgia E Hodes; Madeline L Pfau; Marylene Leboeuf; Sam A Golden; Daniel J Christoffel; Dana Bregman; Nicole Rebusi; Mitra Heshmati; Hossein Aleyasin; Brandon L Warren; Benoit Lebonté; Sarah Horn; Kyle A Lapidus; Viktoria Stelzhammer; Erik H F Wong; Sabine Bahn; Vaishnav Krishnan; Carlos A Bolaños-Guzman; James W Murrough; Miriam Merad; Scott J Russo Journal: Proc Natl Acad Sci U S A Date: 2014-10-20 Impact factor: 11.205
Authors: Laura E Targownik; Kathryn A Sexton; Matthew T Bernstein; Brooke Beatie; Michael Sargent; John R Walker; Lesley A Graff Journal: Am J Gastroenterol Date: 2015-06-16 Impact factor: 10.864
Authors: Samantha Wong; John R Walker; Rachel Carr; Lesley A Graff; Ian Clara; Stephen Promislow; Linda Rogala; Norine Miller; Patricia Rawsthorne; Charles N Bernstein Journal: Can J Gastroenterol Date: 2012-08 Impact factor: 3.522
Authors: Kendra Kamp; Sharon Dudley-Brown; Margaret Heitkemper; Gwen Wyatt; Barbara Given Journal: Res Nurs Health Date: 2019-10-10 Impact factor: 2.228
Authors: Maisa I Abdalla; Robert S Sandler; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Millie D Long Journal: Inflamm Bowel Dis Date: 2016-11 Impact factor: 5.325
Authors: Millie D Long; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Robert S Sandler Journal: J Crohns Colitis Date: 2013-08-06 Impact factor: 9.071